Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

NCT05170685 · clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class

Interventions

Sponsor

Bristol-Myers Squibb